55results about How to "Quickly and accurately grasp the condition" patented technology

The invention belongs to the fields of gene engineering and oncology and discloses a serum / plasma miRNA marker associated with breast cancer and application thereof. The marker is a combination of miR-16, miR-25, miR-222 and miR-324-3p. The maker and primers thereof can be used for preparing a diagnosis kit and assisting early diagnosis of the breast cancer.

The invention relates to a kit for a serum / plasma lncRNA marker related to stomach cancer. The serum / plasma lncRNA marker is combination of MALAT1 and HOTAIR, a primer is a primer for the MALAT1 and the HOTAIR, and the upstream primer sequence and the downstream primer sequence of the MALAT1 are SEQ No.1 and SEQ No.2; the upstream primer and the downstream primer of the HOTAIR are SEQ No.3 and SEQ No.4. By means of the kit, the defect that a kit only adopting one serum / plasma lncRNA as the tumor marker is low in sensitivity and specificity, so that the fault diagnosis rate and the rate of early gastric cancer diagnosis are greatly raised is overcome; by means of the kit, the sensitivity and specificity of disease diagnosis are enhanced, successful development of the lncRNA biological marker is beneficial to auxiliary diagnosis of stomach cancer and provides reference for research of biological markers of other diseases, lncRNA chip detection is adopted to obtain a serum / plasma lncRNA expression profile for disease specificity and abnormity expression, a qRT-PCR method is applied to conduct single verification, and dye method is adopted to conduct verification.

The invention belongs to the fields of genetic engineering and oncology, and discloses a blood serum / blood plasma micro ribonucleic acid (miRNA) marker relevant with pancreatic cancer and application thereof. The marker is formed by combining miR-451 and miR-490-3p. The marker and primers of the marker can be used for preparing a diagnostic kit and are used for the auxiliary diagnosis of pancreatic cancer.

The invention belongs to the fields of gene engineering and reproductive medicine, and discloses a single nucleotide polymorphism (SNP) marker related with clinically cryptogenic non-obstructive azoospermia aided diagnosis and application of the SNP marker. The marker is a combination of rs1014331, rs10765875, rs10889203, rs11066453, rs11167809, rs12097821, rs1990264, rs3000811, rs3130048, rs391129, rs4716515, rs658239, rs6589102, rs7042232, rs7099208, rs7144703, rs7194 and rs985421. The marker can be used for preparing a clinically cryptogenic non-obstructive azoospermia aided diagnosis kit.

The invention belongs to the fields of gene engineering and tumor medicine, and discloses an early stomach cancer assisted diagnosis related SNP (single-nucleotide polymorphism) marker and application thereof. The marker is a combination of rs10737808, rs10193016, rs7607715, rs2904350, rs17312167, rs13168609, rs561443, rs7810066, rs10257532, rs3849222, rs11817406, rs7193854, rs12447431 and rs4790224. The marker can be used for preparing an early stomach cancer assisted diagnosis kit.

The invention discloses a miRNA marker in a serum exosome related to early diagnosis of lung adenocarcinoma and application. The marker is selected from hsa-miR-4516, hsa-miR-342-3p, hsa-miR-199a-3p, hsa-miR-150-5p, hsa-miR-140-3p, hsa-miR-18a-5p, hsa-miR-222-3p, hsa-miR-27a-3p, hsa-miR-29a-3p, hsa-miR-221-3p, hsa-miR-500a-3p, hsa-miR-6126 and hsa-miR-6715a-3p. The marker can effectively separate early lung adenocarcinoma cases from healthy people. The marker and probes thereof can be used for preparing a lung adenocarcinoma early diagnosis kit. The marker has an assisting effect on early diagnosis of lung adenocarcinoma.

The invention belongs to the fields of gene engineering and tumor medicines, and discloses an SNP (Single Nucleotide Polymorphism) marker correlated to assistant diagnosis of primary lung cancer and application thereof. The marker is a combination of the following 63 SNP: rs107401, rs465498, rs663414, rs622917, rs636586, rs741061, rs855641, rs948783, rs1544694, rs1663689, rs2030378, rs2225588, rs2317683, rs2395166, rs2405271, rs2788713, rs3130975, rs4344933, rs4488809 and the like. The marker can be used for preparing an assistant diagnosis kit for the primary lung cancer.

The invention belongs to the fields of gene engineering and tumor medicines, and discloses an SNP (Single Nucleotide Polymorphism) marker correlated to assistant diagnosis of noncardia cancer and application thereof. The marker is a combination of the following 25 SNP: rs1950476, rs238889, rs7973779, rs1445227, rs7528071, rs1549058, rs9841504, rs749130, rs17032274, rs3027247, rs9578831, rs714842, rs17262413, rs16924994, rs13361707, rs12496648, rs2826151, rs12416175, rs3753473, rs7349868, rs60266313 and the like. The marker can be used for preparing an assistant diagnosis kit for the noncardia cancer.

The invention belongs to the fields of genetic engineering and reproductive medicine and discloses an SNP marker of mitochondria DNA related to asthenospermia with unknown clinical causes and application thereof. The marker is a combination of C5601T, T12338C, Al2361G, G13928C, Al5851G, C16179T and G16291A, can be used for preparing an auxiliary diagnosis kit for asthenospermia with unknown clinical causes and has high specificity and sensitivity.

A peripheral blood exosome-sourced liver cancer diagnosis and prognosis marker is disclosed. The marker is exosome-sourced Rab27A protein and / or Rab27B protein. Through western blot detection, it is found that the positive expression rate of the Rab27A protein in a peripheral blood exosome of a patient with liver cancer is obviously higher than that of a common person, and the negative expression rate of the Rab27B protein in the peripheral blood exosome of the patient with liver cancer is obviously higher than that of a common person. Analysis about the abovementioned experiment results in combination with clinical data shows that content abnormity of the Rab27A protein and the Rab27B protein is significantly correlated to occurrence and development of liver cancer; and survival time of patients with positive expression of the Rab27A protein and negative expression of the Rab27B protein is shortened. The diagnosis and prognosis marker provides a method having higher sensitivity and higher specificity for liver cancer diagnosis and prognosis in clinic.

The invention discloses a plasma exosome tRFs marker and an application thereof to breast cancer diagnosis. The marker is an exosome-derived tRF-Ser-AGA-018. The application of the marker includes theoperating steps: A building a unified specimen bank and a database, acquiring blood samples and tissue samples conforming to standards by standard operating procedures, and systematically collectingcomplete clinical data of included crowds; B analyzing tumor-induced exosome-derived tRFs disparity expression spectra in blood, selecting plasma samples of breast cancer cases and healthy persons, breast cancer tissues and para-carcinoma tissues, extracting exosomes, sequencing tRFs and tiRNA and screening out differentially expressed tRFs; C performing QRT-PCR (quantitative reverse transcriptionpolymerase chain reaction) analysis on the screened differentially expressed tRFs in large sample crowds. The tumor-induced exosome tRFs in the blood is a novel biomarker which realizes stability, minimal invasiveness and real-time monitoring, the sensitivity and the specificity of disease diagnosis are greatly improved, and successful development of the non-coding RNA (ribonucleic acid) biomarker is beneficial to breast cancer diagnosis.

The invention relates to a plasma / serum circulation microRNA marker related to mlignnt melnom and application of the marker. The plasma / serum circulation microRNA marker related to mlignnt melnom is combination of miR-610, miR-1224-5p, miR-125a-3p and miR-557. The invention provides the plasma / serum circulation microRNA marker which has the capability of early diagnosis and mlignnt melnom screening and is related to mlignnt melnom, and the application of the marker.

The invention belongs to the fields of genetic engineering and oncology, and discloses an SNP marker related to liver toxicity of platinum type chemotherapeutic medicines and applications thereof. The marker is a composition of rs6681909, rs4140932, rs13131227, rs4446279, rs17053350, rs9402873, rs16878272, rs13267737, rs7008590, rs947853, rs2838566, rs1383888, rs9642723, rs3822296, rs2160046, rs10002931, rs10032941, rs6449138, rs1048037 and rs10086636. The marker and primer probes thereof can be used for preparing a diagnosis kit of the liver toxicity of platinum type chemotherapeutic medicines, and are good in sensitivity and specificity.

The invention belongs to the fields of genetic engineering and oncology and discloses an internal reference for detecting miRNA (micro Ribonucleic Acid) in serum / blood plasma and application of the internal reference. The internal reference is separate miR-484 or miR-191 or a combination of the miR-191 and the miR-484. The internal reference and a primer of the internal reference can be used for preparing an internal reference detection kit which is used for detecting the internal reference of the miRNA in serum / blood plasma.

The invention relates to a clinically unexplained NOA (non-obstructive azoospermia)-related mitochondrial DNA SNP (single nucleotide polymorphism) marker and applications thereof, belonging to the fields of genetic engineering and reproductive medicine. The marker is a combination of the following mitochondrial DNA SNP sites: T3394C, A6881G, G11696A, G13135A, G13928C, A15662G, T15968C, T16224C and G16319A. The marker and specific primers and / or specific probes thereof can be used for auxiliary diagnosis of the clinically unexplained NOA, greatly improving the sensitivity and specificity of diagnosis.

The invention belongs to the field of genetic engineering and reproductive medicine and discloses an SNP marker related to auxiliary diagnosis of non-syndromic congenital heart disease and an application thereof. The SNP marker is composed of rs3789612, rs4140836, rs13391263, rs13101737, rs1400558, rs6872396, rs13189951, rs9266596, rs7863990, rs2433752, rs7259736, rs490514, rs2474937, rs1531070, rs9533839, rs17019472, rs10182004, rs9461938, rs72759270 and rs1886441. The marker can be used for preparing an auxiliary diagnosis kit of the non-syndromic congenital heart disease.

The invention belongs to the technical field of biology and relates to a miRNA landmark for lung cancer tissue typing and an application thereof. The miRNA landmark for lung cancer tissue typing provided by the invention comprises a miRNA-205, a miRNA-21 and a miRNA-26b. The invention also discloses primer probes with the sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, and an application thereof in preparation of a lung cancer tissue typing kit. The miRNA landmark has the beneficial effects that a biomarker with very high diagnostic value (AUC is 1.000, sensitivity is 100% and specificity is 100%) for the lung cancer tissue typing is discovered for the first time and a kit capable of detecting the content of the biomarker in the tissue is provided.

The invention belongs to the fields of genetic engineering and oncology, and discloses a serum / plasma miRNA marker for early diagnosis of noncardiac gastric carcinoma and applications thereof. The marker is a composition of miR-16, miR-25, miR-92a, miR-451 and miR-486-5p. The marker and primers thereof can be used for preparing a diagnosis kit, and used for assistant early diagnosis of the noncardiac gastric carcinoma.

The invention discloses a micro-RNA marker and application thereof to preparation of a product for the diagnosis of a chronic thromboembolic pulmonary hypertension CTEPH disease. The micro-RNA markeris hsa-miR-20a-5p. The invention further discloses a kit; the kit contains a reagent for determining the has-miR-20a-5p marker. The kit for chronic thromboembolic pulmonary hypertension CTEPH miRNA disease detection is quick and convenient and can realize the early diagnosis and the prediction of CTEPH.

The invention belongs to the fields of gene engineering and oncology and discloses a serum / plasma miRNA marker associated with breast cancer and application thereof. The marker is a combination of miR-16, miR-25, miR-222 and miR-324-3p. The maker and primers thereof can be used for preparing a diagnosis kit and assisting early diagnosis of the breast cancer.

The invention belongs to the fields of gene engineering and oncology, and discloses a mammary cancer assisted diagnosis related SNP (single-nucleotide polymorphism) marker and application thereof. The marker is a combination of 32 SNPs, such as rs10152591, rs1037699, rs10487075, rs11645106, rs11663688, rs11768670, rs11910707, rs12972670, rs13038095, rs142255517, rs142895740, rs144600021, rs17128116, rs2053026, rs213212, rs2229300, rs2981582, rs35002951, rs3748140 and the like. The marker can be used for preparing a mammary cancer assisted diagnosis kit.

The invention belongs to the field of genetic engineering and tumor medicine, and discloses a cancer-testis genetic marker related to primary lung cancer auxiliary diagnosis and application thereof. The marker is combination of rs12166583, rs12477419, rs75764106, rs74640907, rs74377505, rs1007089, rs1433646, rs6001675, rs11125117, rs3747093 and rs793598. The marker can be used for preparing primary lung cancer auxiliary diagnosis kit, and has a relatively good clinical application prospect.

The invention belongs to the field of genetic engineering and reproductive medicine and discloses a low frequency SNV marker associated with sporadic non-syndromic CHD (congenital heart disease) auxiliary diagnosis and an application of the low frequency SNV marker. The marker is a combination of 41 low frequency SNVs such as rs75423398, rs7527798, rs200531164, rs6756629, rs139026854, rs79043251, rs1801212, rs4956145, rs7689099, rs145248317, rs34525648, rs16891235, rs13194053, rs41269281, rs41270593, rs3130250 and rs3130379. The marker can be used for preparing a sporadic non-syndromic CHD auxiliary diagnosis kit.

The invention discloses a miRNA marker, a kit and an application for detecting brain injury. The marker is any one or more of;miR-9, miR-124, miR-128a and miR-128b, the kit is used for detecting the content of microRNA markers in cerebrospinal fluid; the marker and the kit can be used for auxiliary diagnosis of brain injury, and are easy to detect, accurate in quantity, good in sensitivity and specificity.

The invention belongs to the field of genetic engineering and oncology, and discloses an SNP marker for assisting in diagnosing non-small cell lung cancer and application thereof. The marker is a combination of rs2293607, rs10429489, rs2517873, rs4573350, rs1200399, rs4236709, rs13167280, rs17038564, rs55768116, rs1853837, rs12265047, rs401681, rs77468143, rs11610143, rs35201538 and rs3817963. Themarker can well distinguish healthy controls and non-small cell lung cancer patients, and can be used for preparing a non-small cell lung cancer auxiliary diagnostic kit.

The invention discloses a micro-RNA marker and application thereof to preparation of a product for the diagnosis of a chronic thromboembolic pulmonary hypertension CTEPH disease. The micro-RNA markeris hsa-miR-20a-5p. The invention further discloses a kit; the kit contains a reagent for determining the has-miR-20a-5p marker. The kit for chronic thromboembolic pulmonary hypertension CTEPH miRNA disease detection is quick and convenient and can realize the early diagnosis and the prediction of CTEPH.

The invention discloses a miRNA marker for detecting non-alcoholic fatty liver, a kit, an application and a detection method, wherein the miRNA marker is any one or more of miR-122-5p, miR-21-5p, miR-192-5p, miR-223-3p, miR-29a-3p, miR-331-3p, miR-30c-5p, miR-182-5p, miR-224-5p and miR-221-5p; the marker and kit can be used for assistant diagnosis of non-alcoholic fatty liver, and are easy to detect, accurate in quantification, and good in sensitivity and specificity.

The invention belongs to the fields of genetic engineering and oncology, and discloses an SNP marker related to liver toxicity of platinum type chemotherapeutic medicines and applications thereof. The marker is a composition of rs6681909, rs4140932, rs13131227, rs4446279, rs17053350, rs9402873, rs16878272, rs13267737, rs7008590, rs947853, rs2838566, rs1383888, rs9642723, rs3822296, rs2160046, rs10002931, rs10032941, rs6449138, rs1048037 and rs10086636. The marker and primer probes thereof can be used for preparing a diagnosis kit of the liver toxicity of platinum type chemotherapeutic medicines, and are good in sensitivity and specificity.

The invention belongs to the fields of gene engineering and oncology, and discloses an SNP marker related with the myelosuppression toxicity of platinum chemotherapeutics and applications thereof. The marker is composed of rs12883763, rs13014982, rs6750741, rs11892526, rs430253, rs7610842, rs12639117, rs623393, rs2051802, rs11968978, rs9390164, rs1485282, rs1904023, rs11026144, rs830379, rs712476, rs8006004, rs6497934, rs6502373, rs9909179, and rs2830451. The marker can be used to prepare a diagnosis kit for detecting the myelosuppression toxicity of platinum chemotherapeutics.